Suppr超能文献

人类辅助生殖技术中的低温生物学。希波克拉底会赞同吗?

Cryobiology in human assisted reproductive technology. Would Hippocrates approve?

作者信息

Bredkjaer H E, Grudzinskas J G

机构信息

Bridge Centre, One St Thomas Street, London, SE1 9RY, UK.

出版信息

Early Pregnancy (Cherry Hill). 2001 Jul;5(3):211-3.

Abstract

Recent advances in human cryobiology have been substantially greater than the first slow step from freezing spermatozoa in animals in Italy, published in 1776 to observing motility in frozen-thawed human sperm in 1938(1). Reports on cryopreservation of rabbit oocytes (1947)(1) and births from fertilised frozen-thawed mice oocytes in 1977(1) were soon followed by the first human pregnancy (1983)(1) and birth (1984)1 following transfer of frozen-thawed embryos after in-vitro fertilisation (IVF). Whereas cryopreservation of human sperm and embryos in tertiary level fertility centres is now commonplace, the full clinical, scientific and sociological consequences of progress in this rapidly moving field are to be determined. These include pregnancy with frozen-thawed human mature, oocytes after conventional IVF (1986)4, intracytoplasmic sperm injection (ICSI)(5) (1996), pregnancies following use of frozen-thawed mature (1995)(5,6) and immature oocytes (1999)(7), ovarian tissue banking (8) and possible autografting (1999)(9) as well as repeated freeze-thawing of male gametes and of embryos (10,11). Cryopreservation of female and male gametes instead of embryos offer solutions of obvious religious, ethical, legal and clinical problems. In addition, there may be benefits in reducing the cost of infertility treatment, improving the safety of fertility treatment with respect to ovarian hyperstimulation syndrome and repeated treatment with controlled ovarian hyperstimulation, prevention of diseases such as sexually transmitted diseases and hereditary disorders and preventing infertility by possible long-term storage of gametes, gonadal tissue and even embryos. The benefits of cryopreservation of sperm, oocytes and embryos in the management of subfertile couples, many being self-evident to some, bear emphasis. Cryopreservation of sperm offers substantial organisational, cost and social advantages in IVF/ICSI treatment, in that it is no longer necessary for both partners to be present at the time of oocyte retrieval, or to have the sperm retrieval done simultaneously, as frozen-thawed sperm (ejaculatory, epididymal or testicular) can be used. This strategy permits men in the latter two categories to be able to support their partners at the time of oocyte retrieval, with the knowledge that their sperm surgically obtained some time previously, is available. It is now clear that, in men with obstructive azoospermia, the use of fresh or frozen-thawed sperm will yield equivalent fertilisation rates following ICSI. In men with non-obstructive azoospermia, with a 60% chance only of obtaining sperm from the testicular aspiration or biopsy, the option could be cryopreservation of the sperm harvested first and later controlled ovarian hyperstimulation of the female partner, to use thawed sperm which will lead to equivalent fertilisation rates using fresh sperm. Thus, one may avoid cost of treatment of the female in those couples who do not wish to use donor sperm as a back-up in the 40% of men from whom sperm is not obtained. Important consequences of cryopreservation of gametes and gonadal tissue are likely to be in the area of prevention of hereditary and familial diseases, as cryopreservation of oocytes, sperm, embryos and blastocysts is exploited fully in pre-implantation genetic diagnosis (PGD) strategies12. Embryo biopsy now permits screening to identify normal embryos from couples who are carriers of known single gene defects and hereditary disorders and the list of these conditions is expanding rapidly. PGD is feasible on frozen-thawed blastomeres even if cells have lysed after thawing, providing information relevant for surviving blastomeres or blastocysts. But what of the gene probes which will soon deluge us on the completion of the Human Genome Project? Can we anticipate benefits and consider proposing that couples with familial disorders, whether degenerative e.g. Type 2 Diabetes, or malignant conditions such as cancer of the ovary, breast and colon? Should we cryopreserve oocytes/sperm/embryos for the purposes of PGD once the markers are available? Cryobiology indeed provides hope now for women and men with neoplastic diseases, who are about to receive oncotherapy for malignancies which inevitably will render them sterile. Men may now freeze epididymal, testicular as well as ejaculatory sperm as ICSI has revolutionalised the treatment of male infertility. It might be likely that testicular tissue from prepubertal boys can be cryopreserved with a reasonable expectation that techniques will soon be developed to effect maturation of spermatogonia in-vivo or in-vitro13. The greatest advance is likely to be for women suffering from reproductive cancer, who may now consider mature and immature oocytes being frozen or vitrified with a reasonable chance of fertilisation by ICSI later, as well as the cryopreservation and storage of ovarian cortex tissue biopsies. Work is proceeding still to refine techniques of in-vitro maturation of frozen-thawed immature oocytes, and the frozen-thawed ovarian cortex tissue slices. The potential benefits will not only be to female fertility for the latter conditions but endocrine disorders as well as by autotransplantation (1999)9. Currently, ovarian tissue banking8 is being considered by women undergoing procedures or treatment which could destroy ovarian function with quite realistic but cautious expectations of preserving ovarian function, but tomorrow women may consider banking ovarian tissue as insurance against childlessness because of the risk of disorders in the reproductive tract (endometriosis, simple recurrent ovarian cysts) and even advancing years. For those who have conceived with surplus oocytes cryopreserved, anonymous oocyte donation is a possibility for the solution of ethical and legal problems. All over Europe, the age of women having their first child is dramatically increasing now being in their late twenties, with likely significant implications in the need to fertility treatment in the Millennium. Society has always been excited but understandably cautious about the prospect of whole body cryopreservation. Hippocrates would have argued that Society could separate medicine and its advances from religious views, dogma and prejudice and, on the present evidence, would probably have looked upon human cryobiology favourably. Human cryobiology is here to stay and society as well as the profession is addressing its relevance. There are clear signs that this technology can and will alleviate suffering by preventing genetic and familial diseases, infections and infertility as well as lowering the cost and social consequences of the treatment. For these reasons, further research in this field should be welcomed and supported.

摘要

人类低温生物学的最新进展比其从1776年意大利首次冷冻动物精子到1938年观察冻融后人类精子活力这一最初的缓慢步伐要大得多。关于兔卵母细胞冷冻保存的报告(1947年)以及1977年冻融小鼠卵母细胞受精后诞生幼崽的报告,很快就迎来了首例人类妊娠(1983年)以及首例体外受精(IVF)后冻融胚胎移植后的婴儿诞生(1984年)。如今,在三级生殖医学中心冷冻保存人类精子和胚胎已很常见,但这一快速发展领域的进展所带来的全部临床、科学和社会学影响仍有待确定。这些进展包括常规IVF后冻融人类成熟卵母细胞妊娠(1986年)、卵胞浆内单精子注射(ICSI)(1996年)、使用冻融成熟卵母细胞(1995年)和未成熟卵母细胞(1999年)后的妊娠、卵巢组织库建立(1999年)以及可能的自体移植(1999年),还有雄配子和胚胎的反复冻融(2000年、2001年)。冷冻保存雌、雄配子而非胚胎为宗教、伦理、法律和临床问题提供了明显的解决方案。此外,在降低不孕治疗成本、提高生育治疗安全性(相对于卵巢过度刺激综合征以及控制性卵巢过度刺激的反复治疗)、预防诸如性传播疾病和遗传性疾病等疾病以及通过可能的配子、性腺组织甚至胚胎的长期保存来预防不孕方面可能存在益处。冷冻保存精子、卵母细胞和胚胎在治疗不育夫妇方面的益处,对一些人来说许多是不言而喻的,值得强调。冷冻保存精子在IVF/ICSI治疗中具有显著的组织、成本和社会优势,因为不再需要夫妻双方在取卵时都在场,也不必同时取精,因为冻融后的精子(射出的、附睾的或睾丸的)都可以使用。这种策略使后两类男性能够在取卵时支持他们的伴侣,因为他们知道之前通过手术获取的精子是可用的。现在很清楚,对于梗阻性无精子症男性,使用新鲜或冻融精子在ICSI后将产生相同的受精率。对于非梗阻性无精子症男性,睾丸穿刺或活检仅60%的机会能获取精子,选择可以是先冷冻保存获取的精子,随后对女性伴侣进行控制性卵巢过度刺激,使用解冻精子,这将产生与使用新鲜精子相同的受精率。因此,对于那些不希望使用供体精子作为备用方案的夫妇,如果40%的男性无法获取精子,就可以避免女性的治疗成本。配子和性腺组织冷冻保存的重要影响可能在于预防遗传性和家族性疾病领域,因为卵母细胞、精子、胚胎和囊胚的冷冻保存在植入前基因诊断(PGD)策略中得到了充分利用。胚胎活检现在允许进行筛查,以从已知单基因缺陷和遗传性疾病携带者夫妇中识别正常胚胎,而且这些疾病的清单正在迅速增加。即使解冻后细胞已裂解,对冻融后的卵裂球进行PGD也是可行的,这能为存活的卵裂球或囊胚提供相关信息。但是,随着人类基因组计划的完成,即将大量涌现的基因探针又如何呢?我们能否预期其益处,并考虑建议患有家族性疾病的夫妇,无论是退行性疾病如2型糖尿病,还是恶性疾病如卵巢癌、乳腺癌和结肠癌?一旦有了标记物,我们是否应该为了PGD而冷冻保存卵母细胞/精子/胚胎?低温生物学确实为患有肿瘤疾病的男女带来了希望,他们即将接受不可避免会导致不育的恶性肿瘤的肿瘤治疗。由于ICSI彻底改变了男性不育的治疗方法,男性现在可以冷冻附睾、睾丸以及射出的精子。很有可能可以冷冻保存青春期前男孩的睾丸组织,并合理预期很快会开发出体内或体外使精原细胞成熟的技术。最大的进展可能在于患有生殖系统癌症的女性,她们现在可以考虑冷冻或玻璃化成熟和未成熟卵母细胞,之后通过ICSI有合理的受精机会,以及冷冻保存和储存卵巢皮质组织活检样本。目前仍在进行工作以完善冻融未成熟卵母细胞以及冻融卵巢皮质组织切片的体外成熟技术。潜在益处不仅在于后一种情况下女性的生育能力,还在于内分泌紊乱以及自体移植(可能性)。目前,正在接受可能破坏卵巢功能的手术或治疗的女性正在考虑建立卵巢组织库,她们怀着相当现实但谨慎的期望来保存卵巢功能,但未来女性可能会考虑建立卵巢组织库,作为因生殖道疾病(子宫内膜异位症、单纯复发性卵巢囊肿)甚至年龄增长导致不育风险的一种保障。对于那些通过冷冻保存多余卵母细胞而受孕的人来说,匿名卵母细胞捐赠是解决伦理和法律问题的一种可能性。在整个欧洲,首次生育的女性年龄现在急剧增加,已到近三十岁,这在千禧年对生育治疗的需求可能会产生重大影响。社会一直对全身冷冻保存的前景既兴奋又可以理解地持谨慎态度。希波克拉底可能会认为,社会可以将医学及其进展与宗教观点、教条和偏见分开,而且根据目前的证据,可能会对人类低温生物学持赞许态度。人类低温生物学已成为现实,社会以及专业人士都在探讨其相关性。有明显迹象表明,这项技术能够而且将会通过预防遗传性和家族性疾病、感染和不育,以及降低治疗成本和社会影响来减轻痛苦。基于这些原因,该领域的进一步研究应受到欢迎和支持。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验